Work

Magnitude of progression-free survival (PFS) improvement and treatment (Tx) duration in metastatic colorectal cancer (mCRC) for bevacizumab (BV) in combination with oxaliplatin-containing regimens: An analysis of two phase III studies

Year: 2007

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2007.25.18_suppl.4073

Authors: B. J. Giantonio, N. J. Meropol, P. J. Catalano, V. Ng, R. Oliver, F. Sirzen, S. Leonard, J. Cassidy, A. B. Benson

Institutions: Northwestern University, F. Hoffmann-La Roche AG, Fox Chase Cancer Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, University of Glasgow, University of Pennsylvania

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2602809045

Cites:

Cited by: 5

Related to: 10